Program-Based Lung Cancer Care: A Prospective Observational Tumor Registry Linkage Study.
Early detection
Lung cancer screening
Lung nodule programs
Multidisciplinary Care
Public health
Quality of care
Journal
JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967
Informations de publication
Date de publication:
Feb 2024
Feb 2024
Historique:
received:
21
09
2023
revised:
19
12
2023
accepted:
21
12
2023
medline:
7
2
2024
pubmed:
7
2
2024
entrez:
7
2
2024
Statut:
epublish
Résumé
Low-dose computed tomography screening (LDCT) and lung nodule programs (LNP) promote early lung cancer detection, improve survival; Multidisciplinary Care Programs (MDC) promote guideline-concordant care. The impact of such program-based care on "real-world" lung cancer survival is unquantified. We evaluated outcomes of lung cancer care delivered through structured programs in a community health care system. We conducted a cohort study linking institutional prospective observational LDCT, LNP and MDC databases with Tumor Registry of Baptist Cancer Center facilities. We categorized all patients diagnosed with lung cancer between 2011 and 2021 into program-based care versus non-program-based care cohorts. We compared patient characteristics, stage distribution, treatment modalities, survival and mortality in each pathway of care. Of 12,148 patients, 237, 1,165, 1,140 and 9,606 were diagnosed through the LDCT, LNP, MDC or no program, respectively; non-program-based care sequentially diminished from 96.3% to 66.5%, diagnosis through LDCT increased from 0.5% to 7.1%, LNP from 3.5% to 20.8%; and MDC alone decreased from a high of 12.8% in 2014 to 5.6% in 2021. Program-based care was associated with earlier stage (p < 0.001), higher surgical resection rates ( Program-based care was associated with substantially better survival. Increasing access to program-based care should be explored as a matter of urgent public policy.
Identifiants
pubmed: 38322712
doi: 10.1016/j.jtocrr.2023.100629
pii: S2666-3643(23)00172-8
pmc: PMC10845058
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100629Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
Dr. Osarogiagbon reports as patent, specimen collection kit; stocks: Bridge BIO, Eli Lilly, Gilead Sciences, Pfizer; consultant: AstraZeneca, GE Healthcare, Genentech/Roche, Median Technologies, National Cancer Institute, Tryptych Healthcare Partners. Dr. Matthews reports as Stocks, Pfizer and Boston Scientific. Dr. Smeltzer reports as Research consultant, Association of Community Cancer Centers. Dr. Faris reports as personal fees from Biodesix. The remaining authors declare no conflict of interest.